Last reviewed · How we verify
Schaper & Bruemmer GmbH & Co KG — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Black Cohosh (iCR) or tibolone | Black Cohosh (iCR) or tibolone | phase 3 | Herbal extract / Selective tissue estrogenic activity regulator (STEAR) | Serotonin receptors (Black Cohosh); estrogen receptor, progesterone receptor, androgen receptor (tibolone) | Women's Health / Endocrinology |
Therapeutic area mix
- Women's Health / Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Schaper & Bruemmer GmbH & Co KG:
- Schaper & Bruemmer GmbH & Co KG pipeline updates — RSS
- Schaper & Bruemmer GmbH & Co KG pipeline updates — Atom
- Schaper & Bruemmer GmbH & Co KG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Schaper & Bruemmer GmbH & Co KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/schaper-bruemmer-gmbh-co-kg. Accessed 2026-05-17.